Source: European Parliament
Question for written answer E-001223/2025
to the Commission
Rule 144
Loucas Fourlas (PPE)
Type 1 diabetes mellitus is a chronic autoimmune disease affecting thousands of children across the European Union, requiring continuous and specialised support with medical technology to effectively manage the condition. However, access to state-of-the-art medical tech solutions, such as continuous glucose monitoring systems, insulin pumps and automated insulin delivery systems, is not uniform across Member States, with smaller states, such as Cyprus, facing significant challenges. Unequal access to these critical technologies has a direct impact on the quality of life of patients, especially children, as well as on public health costs. Urgent action is needed because access to state-of-the-art technology is a fundamental right for all European citizens.
In view of the above:
- 1.How does the Commission intend to ensure that all European citizens, including those living in smaller Member States, have access to the most advanced medical tech solutions for managing type 1 diabetes?
- 2.Does the Commission intend to propose a European framework for the adoption of national diabetes strategies, including minimum standards for accessing new technologies for managing type 1 diabetes mellitus?
Submitted: 24.3.2025